Cassava Sciences INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Filana Therapeutics reports significant progress in resolving legal matters and a clinical hold on its simufilam IND, while R&D expenses decrease due to program shifts.
Filana Therapeutics reports a net loss of $10.3 million for Q1 2026 as it pivots focus to TSC-related epilepsy research.
Cassava Sciences reported a net loss of $10.8 million for Q3 2025, discontinuing its Alzheimer's program to focus on TSC-related epilepsy with a new Yale license.
Cassava Sciences reports significant losses and discontinues its Alzheimer's drug program, pivoting to a new epilepsy indication while facing substantial legal costs.
Cassava Sciences is pivoting its focus to Tuberous Sclerosis Complex (TSC) after Phase 3 trials for its Alzheimer's drug, simufilam, failed to meet endpoints, leading to the discontinuation of its Alzheimer's program.
10-Q: Cassava Sciences Reports Third Quarter 2024 Financial Results and Provides Clinical Program Updates
Cassava Sciences' Phase 3 Alzheimer's drug Simufilam shows promise in trials, with top-line results for the 52-week study expected by the end of 2024, despite ongoing legal challenges and leadership changes.
Cassava Sciences' Q2 2024 report highlights progress in its Phase 3 Alzheimer's drug trials, significant financial changes due to a warrant distribution, and major leadership transitions amid ongoing legal and regulatory challenges.
Cassava Sciences reported a net income of $25 million for the first quarter of 2024, primarily due to a gain from the change in fair value of warrant liabilities.